Abstract | AIM: MATERIAL AND METHODS: A total of 66 patients underwent molecular targeted-therapies at the Kurume University between May 2008 and April 2014. Medical records were retrieved and analyzed retrospectively. RESULTS: The median OS was 25.9 [95% confidence interval (CI)=18.3-33.7] months. The median OS stratified by the Memorial Sloan Kettering Cancer Center risk classification was 49.3, 28.6 and 18.3 months for the favorable-, intermediate- and poor-risk groups, respectively. Univariate analyses for various factors revealed gender, pre-treatment C-reactive protein (CRP) level, best response to first-line treatment, the number of molecular targeted agents and the duration of first-line treatment with a median of 6 months, as prognostic variables. Multivariate analyses showed than two or more than three molecular targeted agents [two: hazard ratio (HR)=0.351, 95% CI=0.121-0.901; more than three: HR=0.193, 95% CI=0.069-0.495] and a duration of first-line treatment of more than 6 months (HR=0.203, 95% CI=0.078-0.498) to be independent prognostic factors. CONCLUSION: Our results suggest that the duration of first-line treatment with molecular targeted-therapies is the strongest prognostic factor in patients with mRCC.
|
Authors | Kosuke Ueda, Shigetaka Suekane, Kiyoaki Nishihara, Naoyuki Ogasawara, Hirofumi Kurose, Shuichiro Hayashi, Katsuaki Chikui, Shunsuke Suyama, Makoto Nakiri, Mitsunori Matsuo, Tsukasa Igawa |
Journal | Anticancer research
(Anticancer Res)
Vol. 35
Issue 6
Pg. 3415-21
(Jun 2015)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 26026104
(Publication Type: Journal Article)
|
Copyright | Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
|
Topics |
- Adult
- Aged
- C-Reactive Protein
(genetics)
- Carcinoma, Renal Cell
(drug therapy, epidemiology, pathology)
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Molecular Targeted Therapy
- Neoplasm Metastasis
- Prognosis
- Treatment Outcome
|